Special Issue "Adverse Drug Reactions and Gender Differences"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: 31 December 2021.
Interests: pharmacovigilance; pharmacoepidemiology; prescriptive appropriateness and clinical research both pre- and postmarketing
Interests: pharmacovigilance; pharmacoepidemiology
In the era of personalized and precision medicine, gender differences continue to be a “grey zone” that requires better definition, especially in terms of drug response and tolerability. Many studies have attempt to associate gender difference with a specific drug response or drug toxicity, but more evidence is needed to bridge the gap. In terms of the drug safety profile, several studies suggest that women are more exposed to the risk of adverse drug reaction (ADR) occurrence than men; this difference could be due to a combination of sex differences, such as weight, height, body surface area, fat mass, plasma volume, total amount of body water, biological differences, and hormonal changes, and gender differences, including psychological, behavioral, and/or cultural differences. Therefore, gender and sex differences could result in different drug tolerability in terms of ADR frequency and seriousness. In this context, advances in pharmacology are essential to understand the gender differences associated with pharmacological treatments, with the aim of better defining the mechanisms underlying the differences in responses to drugs that, in turn, influence their tolerability. Considering that all women are still phased out from clinical trials, evidence from real world data is an important tool for identifying the true safety profiles of medicinal products in populations that have not been adequately studied, in order to promote gender-oriented and appropriate drug prescription. Although the data available regarding the impact of gender on the safety profiles of medicinal products shows a prevalence of ADR occurrence amongst females over males, gender-specific pharmacovigilance activities must be undertaken in order to reduce the risks associated with the use of medicinal products and to conduct a risk/benefit assessment in greater detail to elucidate the differences between men and women in terms of pharmacokinetics and pharmacodynamics.
In this Special Issue, experts are invited to submit clinical trial, experimental, original, and review articles that contribute to improving the understanding of the different drug safety profiles related to gender differences.
Dr. Concetta Rafaniello
Prof. Annalisa Capuano
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- gender differences
- adverse drug reaction
- real world data
- randomized clinical trial